Rafe Swan | Getty Images
"Halftime Report" trader Jon Najarian bought shares of a small-cap biotechnology stock for his CNBC Pro model portfolio after spotting unusual activity in the options market.
On Tuesday, the trader scooped up shares of Amicus Therapeutics, a biotechnology firm involved in the development of drugs for rare diseases.
So far this year, the value of the company was reduced by 42 percent, placing its market cap at $600 million, as investors exited positions in high beta names.
As the stock hovers near a 52-week low, however, Najarian believes a number of bold options bets signal a rally in the stock ahead.
Here is where the options trader sees the fast money headed:
